Woburn, MA – May 24, 2021—Alloplex Biotherapeutics is pleased to announce its participation at the 2021 ASCO Conference to be held June 4 – 8, 2021, with the acceptance of its abstract for oral presentation.
Alloplex CEO Frank Borriello stated, “I am thrilled that we will get a chance to showcase the exciting results stemming from our collaboration with Dr. Jennifer Brown of the Dana Farber Cancer Institute documenting the nature of SUPLEXA therapeutic cells made from CLL patients”.
SUPLEXA Therapeutic Cells are an autologous cellular therapy intended to treat cancer. They are manufactured from peripheral white blood cells (PBMC). Following a short ex vivo activation procedure, the PBMC are differentiated into a mixed population of cells comprised of NK, NK-T and T cells. SUPLEXA therapeutic cells are capable of recognizing and lysing a broad range of tumor cells without harming normal cells.
Alloplex Biotherapeutics is a privately held, Boston-based, preclinical stage, cellular therapeutics company founded in 2016 by its CEO Dr. Frank Borriello, MD, PhD.